Dr. Edith P. Mitchell M.D. serves as Director of the Company. Dr. Mitchell currently serves as clinical professor, Department of Medicine and Medical Oncology at Sidney Kimmel Medical College at Thomas Jefferson University, and as associate director for Diversity Programs and director of the Center to Eliminate Cancer Disparities for the Sidney Kimmel Cancer Center at Thomas Jefferson University. Dr. Mitchell joined Thomas Jefferson University in 1995. Dr. Mitchell currently serves on the National Cancer Institute (NCI) Review Panel and the Cancer Investigations Review Committee, the Clinical Trials and Translational Research Advisory Committee, serves as co-chair of the NCI Disparities Committee, and is a member of the NIH Council of Councils. Dr. Mitchell was selected to serve as a member of the NCI’s Blue Ribbon Panel convened to advise the National Cancer Advisory Board on Vice President Biden’s National Cancer Moonshot Initiative. Dr. Mitchell is a Master of the American College of Physicians, a Fellow of the College of Physicians of Philadelphia, and member of the American Medical Association, the National Medical Association, Aerospace Medical Association, Association of Military Surgeons, the Medical Society of Eastern Pennsylvania, the ECOG/ACRIN Cancer Research Group, and the Radiation Therapy Oncology Group. In 2019, Dr. Mitchell began service as a member of the President’s Cancer Panel. Dr. Mitchell holds leadership positions in the American Society of Clinical Oncology and served as the 116th President of the National Medical Association serving from August 2015 to August 2016. She also serves as the Editor-in-Chief of the Journal of the National Medical Association and on the board of Trustees for Geisinger Commonwealth Medical College and Tennessee State University. Dr. Mitchell holds a B.S. in biochemistry from Tennessee State University and an M.D. from Medical College of Virginia. She completed a residency at Meharry Medical College and a fellowship at Georgetown University Hospital.
Edith's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.
Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over $52,808,904 worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth $85,214,510 . The most active insiders traders include Holdings A/S Novo, Street Partners Llc Adams et Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of $1,530,854. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth $34,600.
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: